Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Accured Expenses (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Change in Accured Expenses for 15 consecutive years, with $76.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 1.03% year-over-year to $76.5 million, compared with a TTM value of $160.2 million through Dec 2025, up 269.12%, and an annual FY2025 reading of $160.2 million, up 269.12% over the prior year.
  • Change in Accured Expenses was $76.5 million for Q4 2025 at Neurocrine Biosciences, up from $55.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $124.4 million in Q3 2023 and bottomed at -$98.3 million in Q4 2023.
  • Average Change in Accured Expenses over 4 years is $20.3 million, with a median of $15.5 million recorded in 2025.
  • Peak annual rise in Change in Accured Expenses hit 178.64% in 2024, while the deepest fall reached 467.28% in 2024.
  • Year by year, Change in Accured Expenses stood at $11.0 million in 2021, then plummeted by 993.64% to -$98.3 million in 2023, then soared by 178.64% to $77.3 million in 2024, then fell by 1.03% to $76.5 million in 2025.
  • Business Quant data shows Change in Accured Expenses for NBIX at $76.5 million in Q4 2025, $55.8 million in Q3 2025, and $15.5 million in Q2 2025.